Screener
Turn Therapeutics Inc. TTRX Q3 2026 earnings
Reported November 12, 2026 · Before market open
EPS-$0.21Miss by $0.12
EPS estimate-$0.09
“The results from our full Stage 1 trial population give us an important look at how patients responded to GX-03 across a wide range of disease severity and extent. We took what we learned from the initial trial and used it to refine our ongoing Phase 2b trial.”
Next report
Date not yet announcedVersus estimates
Diluted EPS
Q3 2026-$0.21Miss by $0.12
Q2 2026-$0.20Miss by $0.18Q1 2026-$0.03Miss by $0.01Q4 2025-$0.09Miss by $0.04Q3 2025-$0.07FAQ
- When did Turn Therapeutics Inc. report Q3 2026 earnings?
- Turn Therapeutics Inc. (TTRX) reported Q3 2026 earnings on November 12, 2026 before market open.
- What were Turn Therapeutics Inc.'s Q3 2026 revenue and EPS?
- Turn Therapeutics Inc. reported eps of $-0.21 for Q3 2026.
- Did Turn Therapeutics Inc. beat estimates in Q3 2026?
- EPS missed the consensus estimate of $-0.09 by $0.12.
- How did Turn Therapeutics Inc.'s Q3 2026 results compare year-over-year?
- Compared to the same quarter a year prior, eps declined 200.0% from $-0.07.
- Where can I find Turn Therapeutics Inc.'s Q3 2026 SEC filings?
- You can read the 8-K earnings release (0001213900-26-117180) and the 10-Q periodic report (0001213900-26-117186) directly on SEC EDGAR. The filing index links above go to sec.gov.
